LU82224A1 - Nouveaux 3-(1-imidazolylalkyl)indoles, leur procede de production et composition pharmaceutique les contenant - Google Patents

Nouveaux 3-(1-imidazolylalkyl)indoles, leur procede de production et composition pharmaceutique les contenant Download PDF

Info

Publication number: LU82224A1
Authority: LU; Luxembourg
Prior art keywords: group; formula; compound; indole; imidazolylmethyl
Prior art date: 1979-03-07

Application number

LU82224A

Other languages

English (en)

French (fr)

Inventor

R Dickinson

P Cross

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-03-07

Filing date

1980-03-05

Publication date

1980-06-06

1980-03-05 Application filed by Pfizer filed Critical Pfizer

1980-06-06 Publication of LU82224A1 publication Critical patent/LU82224A1/fr

Links

238000000034 method Methods 0.000 title claims description 33
238000004519 manufacturing process Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
230000008569 process Effects 0.000 title claims description 7
150000002475 indoles Chemical class 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims description 130
-1 C 1 -C 4 alkoxy Chemical group 0.000 claims description 67
125000000217 alkyl group Chemical group 0.000 claims description 34
238000006243 chemical reaction Methods 0.000 claims description 27
238000011282 treatment Methods 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 17
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 14
108010069102 Thromboxane-A synthase Proteins 0.000 claims description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
230000009471 action Effects 0.000 claims description 12
108010064377 prostacyclin synthetase Proteins 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 9
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 8
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
150000001450 anions Chemical class 0.000 claims description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
229910052794 bromium Inorganic materials 0.000 claims description 6
239000000460 chlorine Substances 0.000 claims description 6
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
239000002168 alkylating agent Substances 0.000 claims description 5
229940100198 alkylating agent Drugs 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
125000003831 tetrazolyl group Chemical group 0.000 claims description 3
MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
125000003373 pyrazinyl group Chemical group 0.000 claims description 2
125000002098 pyridazinyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
150000002460 imidazoles Chemical class 0.000 claims 1
229910052740 iodine Chemical group 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 93
239000000203 mixture Substances 0.000 description 93
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 81
239000000243 solution Substances 0.000 description 81
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 74
229910052757 nitrogen Inorganic materials 0.000 description 56
238000004458 analytical method Methods 0.000 description 55
229910052739 hydrogen Inorganic materials 0.000 description 55
230000008018 melting Effects 0.000 description 46
238000002844 melting Methods 0.000 description 46
239000000047 product Substances 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
238000009835 boiling Methods 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
238000002425 crystallisation Methods 0.000 description 27
230000008025 crystallization Effects 0.000 description 27
239000003208 petroleum Substances 0.000 description 27
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 22
239000007787 solid Substances 0.000 description 20
239000000126 substance Substances 0.000 description 20
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
239000000741 silica gel Substances 0.000 description 18
229910002027 silica gel Inorganic materials 0.000 description 18
239000003921 oil Substances 0.000 description 17
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 17
238000010992 reflux Methods 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 16
108090000790 Enzymes Proteins 0.000 description 16
210000001772 blood platelet Anatomy 0.000 description 15
239000002904 solvent Substances 0.000 description 15
238000010828 elution Methods 0.000 description 14
238000001704 evaporation Methods 0.000 description 14
230000008020 evaporation Effects 0.000 description 14
NLWHFXUNVQSMMJ-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethanamine Chemical compound C12=CC=CC=C2N(CCN)C=C1CC1=NC=CN1 NLWHFXUNVQSMMJ-UHFFFAOYSA-N 0.000 description 13
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 13
229960001123 epoprostenol Drugs 0.000 description 13
238000012360 testing method Methods 0.000 description 13
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 13
239000004202 carbamide Substances 0.000 description 12
238000001914 filtration Methods 0.000 description 12
239000012535 impurity Substances 0.000 description 12
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
238000003756 stirring Methods 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
AYGFLNDNSWHEQD-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 AYGFLNDNSWHEQD-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
239000000155 melt Substances 0.000 description 8
150000003180 prostaglandins Chemical class 0.000 description 8
GYLUOCFMFMJROH-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-1h-indole Chemical class C=1NC2=CC=CC=C2C=1CC1=NC=CN1 GYLUOCFMFMJROH-UHFFFAOYSA-N 0.000 description 7
UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 7
208000019695 Migraine disease Diseases 0.000 description 7
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
235000011087 fumaric acid Nutrition 0.000 description 7
206010027599 migraine Diseases 0.000 description 7
229940094443 oxytocics prostaglandins Drugs 0.000 description 7
229910000104 sodium hydride Inorganic materials 0.000 description 7
239000012312 sodium hydride Substances 0.000 description 7
230000002792 vascular Effects 0.000 description 7
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000001530 fumaric acid Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
239000012265 solid product Substances 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
208000006011 Stroke Diseases 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000012043 crude product Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000007858 starting material Substances 0.000 description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 4
RLVMREBBTNSQLD-UHFFFAOYSA-N 3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propan-1-amine Chemical compound C12=CC=CC=C2N(CCCN)C=C1CC1=NC=CN1 RLVMREBBTNSQLD-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
206010008190 Cerebrovascular accident Diseases 0.000 description 4
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
206010019233 Headaches Diseases 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
239000002585 base Substances 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
MMTQOPYULGPLGP-UHFFFAOYSA-N ethyl 2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]acetate Chemical compound C12=CC=CC=C2N(CC(=O)OCC)C=C1CC1=NC=CN1 MMTQOPYULGPLGP-UHFFFAOYSA-N 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
231100000869 headache Toxicity 0.000 description 4
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
229940114079 arachidonic acid Drugs 0.000 description 3
235000021342 arachidonic acid Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
239000012948 isocyanate Substances 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
210000001589 microsome Anatomy 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000000725 suspension Substances 0.000 description 3
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 3
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
NGAGGQFPPLZNBD-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanenitrile Chemical compound OC(=O)\C=C\C(O)=O.C12=CC=CC=C2N(CCC#N)C=C1CC1=NC=CN1 NGAGGQFPPLZNBD-WLHGVMLRSA-N 0.000 description 2
QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 2
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
RTMPJTRCJABAMV-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)-1h-indol-2-yl]propanenitrile Chemical compound N#CC(C)C=1NC2=CC=CC=C2C=1CC1=NC=CN1 RTMPJTRCJABAMV-UHFFFAOYSA-N 0.000 description 2
SWAPJEUGWQSFJX-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]acetamide Chemical compound C12=CC=CC=C2N(CC(=O)N)C=C1CC1=NC=CN1 SWAPJEUGWQSFJX-UHFFFAOYSA-N 0.000 description 2
OLWCXDSZSGVCAS-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC=CC=C2N(CC(=O)O)C=C1CC1=NC=CN1 OLWCXDSZSGVCAS-UHFFFAOYSA-N 0.000 description 2
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
LCNLDGYZJLITHP-UHFFFAOYSA-N 3-[3-(1h-imidazol-2-ylmethyl)-5-methoxyindol-1-yl]propanenitrile Chemical compound C12=CC(OC)=CC=C2N(CCC#N)C=C1CC1=NC=CN1 LCNLDGYZJLITHP-UHFFFAOYSA-N 0.000 description 2
PCYRLLSTOAPEHH-UHFFFAOYSA-N 3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanoic acid Chemical compound C12=CC=CC=C2N(CCC(=O)O)C=C1CC1=NC=CN1 PCYRLLSTOAPEHH-UHFFFAOYSA-N 0.000 description 2
IAJMSSVNFLHCPF-UHFFFAOYSA-N 3-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CN2C3=CC=CC=C3C(CC=3NC=CN=3)=C2)=C1 IAJMSSVNFLHCPF-UHFFFAOYSA-N 0.000 description 2
FRXJYUFHAXXSAL-UHFFFAOYSA-N 3-chloro-n-phenylpropanamide Chemical compound ClCCC(=O)NC1=CC=CC=C1 FRXJYUFHAXXSAL-UHFFFAOYSA-N 0.000 description 2
KPPJRNUWGDJZEI-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 KPPJRNUWGDJZEI-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000700159 Rattus Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
208000032109 Transient ischaemic attack Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
KVFHLLUCXNFZIH-UHFFFAOYSA-N ethyl 4-[[3-(1h-imidazol-2-ylmethyl)-5-methoxyindol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1CN1C2=CC=C(OC)C=C2C(CC=2NC=CN=2)=C1 KVFHLLUCXNFZIH-UHFFFAOYSA-N 0.000 description 2
NYJBZPPCZUARDW-UHFFFAOYSA-N ethyl 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1CN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 NYJBZPPCZUARDW-UHFFFAOYSA-N 0.000 description 2
QJXFLISMTLVAPK-UHFFFAOYSA-N ethyl 4-indol-1-ylbutanoate Chemical compound C1=CC=C2N(CCCC(=O)OCC)C=CC2=C1 QJXFLISMTLVAPK-UHFFFAOYSA-N 0.000 description 2
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
230000006870 function Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 2
WKWJJEWTFDFRRO-UHFFFAOYSA-N methyl n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]carbamate Chemical compound C12=CC=CC=C2N(CCNC(=O)OC)C=C1CC1=NC=CN1 WKWJJEWTFDFRRO-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
ZNYDHKJWXHYAAR-UHFFFAOYSA-N n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]acetamide Chemical compound C12=CC=CC=C2N(CCNC(=O)C)C=C1CC1=NC=CN1 ZNYDHKJWXHYAAR-UHFFFAOYSA-N 0.000 description 2
RJIVXKUCTKVYRX-UHFFFAOYSA-N n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 RJIVXKUCTKVYRX-UHFFFAOYSA-N 0.000 description 2
SBGFWCFNACEISG-UHFFFAOYSA-N n-[3-[5-bromo-3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanoyl]benzamide Chemical compound C1=C(CC=2NC=CN=2)C2=CC(Br)=CC=C2N1CCC(=O)NC(=O)C1=CC=CC=C1 SBGFWCFNACEISG-UHFFFAOYSA-N 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
239000004533 oil dispersion Substances 0.000 description 2
LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
239000012071 phase Substances 0.000 description 2
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000001226 reprecipitation Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
201000010875 transient cerebral ischemia Diseases 0.000 description 2
238000001665 trituration Methods 0.000 description 2
QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
FWDQSXPZRIMPSQ-OLYGTSNOSA-N (5z,8z,11z,14e)-15-hydroxyicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C(O)=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O FWDQSXPZRIMPSQ-OLYGTSNOSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
SKJFTWMIXZFOBU-WLHGVMLRSA-N (e)-but-2-enedioic acid;1h-indole Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2NC=CC2=C1 SKJFTWMIXZFOBU-WLHGVMLRSA-N 0.000 description 1
LEBXXAHMDIOJFS-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propyl]isoindole-1,3-dione Chemical compound OC(=O)\C=C\C(O)=O.O=C1C2=CC=CC=C2C(=O)N1CCCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 LEBXXAHMDIOJFS-WLHGVMLRSA-N 0.000 description 1
GMENRYHNSQKRLR-JITBQSAISA-N (e)-but-2-enedioic acid;3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanoic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O.C12=CC=CC=C2N(CCC(=O)O)C=C1CC1=NC=CN1 GMENRYHNSQKRLR-JITBQSAISA-N 0.000 description 1
ZQHONWVXCFHCBE-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzonitrile Chemical compound OC(=O)\C=C\C(O)=O.N#CC1=CC=CC(CN2C3=CC=CC=C3C(CC=3NC=CN=3)=C2)=C1 ZQHONWVXCFHCBE-WLHGVMLRSA-N 0.000 description 1
UJUGIDKMUFPYHC-WLHGVMLRSA-N (e)-but-2-enedioic acid;ethyl 4-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]butanoate Chemical compound OC(=O)\C=C\C(O)=O.C12=CC=CC=C2N(CCCC(=O)OCC)C=C1CC1=NC=CN1 UJUGIDKMUFPYHC-WLHGVMLRSA-N 0.000 description 1
HAFWELDDNUXLCK-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O HAFWELDDNUXLCK-TYYBGVCCSA-N 0.000 description 1
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
ILGPJIAGKMKHPE-UHFFFAOYSA-N 1-(5-chloro-1h-indol-3-yl)-n,n-dimethylmethanamine Chemical compound C1=C(Cl)C=C2C(CN(C)C)=CNC2=C1 ILGPJIAGKMKHPE-UHFFFAOYSA-N 0.000 description 1
JSFATNQSLKRBCI-VAEKSGALSA-N 15-HETE Natural products CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 1
FTPUNZLSDBAKPC-UHFFFAOYSA-N 2-(1h-imidazol-2-ylmethyl)-1h-indole Chemical compound C=1C2=CC=CC=C2NC=1CC1=NC=CN1 FTPUNZLSDBAKPC-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
LRQINTWIZCYRCC-UHFFFAOYSA-N 2-[2-cyclopropyl-3-(1h-imidazol-2-ylmethyl)-1h-indol-4-yl]propanoic acid Chemical compound N=1C=CNC=1CC=1C=2C(C(C(O)=O)C)=CC=CC=2NC=1C1CC1 LRQINTWIZCYRCC-UHFFFAOYSA-N 0.000 description 1
PNOKUQJYJXOXBD-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)-1h-indol-2-yl]propanamide Chemical compound NC(=O)C(C)C=1NC2=CC=CC=C2C=1CC1=NC=CN1 PNOKUQJYJXOXBD-UHFFFAOYSA-N 0.000 description 1
NDLQIWJGAXPIQZ-UHFFFAOYSA-N 2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethanol Chemical compound C12=CC=CC=C2N(CCO)C=C1CC1=NC=CN1 NDLQIWJGAXPIQZ-UHFFFAOYSA-N 0.000 description 1
XOJUZHMGRFWIHQ-UHFFFAOYSA-N 2-[5-bromo-3-(1h-imidazol-2-ylmethyl)-1h-indol-2-yl]propanoic acid Chemical compound OC(=O)C(C)C=1NC2=CC=C(Br)C=C2C=1CC1=NC=CN1 XOJUZHMGRFWIHQ-UHFFFAOYSA-N 0.000 description 1
POOMHJDYVILILI-UHFFFAOYSA-N 2-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzonitrile Chemical compound N#CC1=CC=CC=C1CN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 POOMHJDYVILILI-UHFFFAOYSA-N 0.000 description 1
JCFDLGDOHBRADK-UHFFFAOYSA-N 2-amino-1-(4-methylphenyl)-4-phenylpyrrole-3-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C(N)=C(C#N)C(C=2C=CC=CC=2)=C1 JCFDLGDOHBRADK-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
IKCZUPRWPVLSLF-UHFFFAOYSA-N 2-methoxy-1h-indole Chemical compound C1=CC=C2NC(OC)=CC2=C1 IKCZUPRWPVLSLF-UHFFFAOYSA-N 0.000 description 1
KHIKPAVBCWEWLG-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-1-[2-(2h-tetrazol-5-yl)ethyl]indole Chemical compound N1=NNN=C1CCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 KHIKPAVBCWEWLG-UHFFFAOYSA-N 0.000 description 1
NRNUJNRHZRLMGP-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-2-propan-2-yl-1h-indole Chemical compound CC(C)C=1NC2=CC=CC=C2C=1CC1=NC=CN1 NRNUJNRHZRLMGP-UHFFFAOYSA-N 0.000 description 1
NWTSCLIQSBYDMR-UHFFFAOYSA-N 3-(1h-imidazol-2-ylmethyl)-5-methoxy-1h-indole Chemical compound C12=CC(OC)=CC=C2NC=C1CC1=NC=CN1 NWTSCLIQSBYDMR-UHFFFAOYSA-N 0.000 description 1
CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
FGTKEKMWUHXOEB-UHFFFAOYSA-N 3-[3-(1h-imidazol-2-ylmethyl)-2-propan-2-ylindol-1-yl]propanamide Chemical compound C12=CC=CC=C2N(CCC(N)=O)C(C(C)C)=C1CC1=NC=CN1 FGTKEKMWUHXOEB-UHFFFAOYSA-N 0.000 description 1
AMBCKBSOJFTRNS-UHFFFAOYSA-N 3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanenitrile Chemical compound C12=CC=CC=C2N(CCC#N)C=C1CC1=NC=CN1 AMBCKBSOJFTRNS-UHFFFAOYSA-N 0.000 description 1
KYJDMVPDLNWAJH-UHFFFAOYSA-N 3-[5-bromo-3-(1h-imidazol-2-ylmethyl)indol-1-yl]propanoic acid Chemical compound C12=CC(Br)=CC=C2N(CCC(=O)O)C=C1CC1=NC=CN1 KYJDMVPDLNWAJH-UHFFFAOYSA-N 0.000 description 1
KKIACXVZELGHLZ-UHFFFAOYSA-N 3-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzonitrile Chemical compound N#CC1=CC=CC(CN2C3=CC=CC=C3C(CC=3NC=CN=3)=C2)=C1 KKIACXVZELGHLZ-UHFFFAOYSA-N 0.000 description 1
VITGGSSBWKUFGR-UHFFFAOYSA-N 3-indol-1-ylpropanamide Chemical class C1=CC=C2N(CCC(=O)N)C=CC2=C1 VITGGSSBWKUFGR-UHFFFAOYSA-N 0.000 description 1
AQVTZBHZFUIILH-UHFFFAOYSA-N 3-indol-1-ylpropanenitrile Chemical compound C1=CC=C2N(CCC#N)C=CC2=C1 AQVTZBHZFUIILH-UHFFFAOYSA-N 0.000 description 1
CQQSQBRPAJSTFB-UHFFFAOYSA-N 4-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-N 0.000 description 1
QYHXYOVTPLVREB-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)-5-methoxyindol-1-yl]methyl]benzoic acid Chemical compound C1=C(CC=2NC=CN=2)C2=CC(OC)=CC=C2N1CC1=CC=C(C(O)=O)C=C1 QYHXYOVTPLVREB-UHFFFAOYSA-N 0.000 description 1
XEPRPWIABWGYEV-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]-n-(1,3-thiazol-2-yl)benzamide Chemical compound C=1C=C(CN2C3=CC=CC=C3C(CC=3NC=CN=3)=C2)C=CC=1C(=O)NC1=NC=CS1 XEPRPWIABWGYEV-UHFFFAOYSA-N 0.000 description 1
LJPPCFXGZAHVMB-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]-n-pyridin-2-ylbenzamide Chemical compound C=1C=C(CN2C3=CC=CC=C3C(CC=3NC=CN=3)=C2)C=CC=1C(=O)NC1=CC=CC=N1 LJPPCFXGZAHVMB-UHFFFAOYSA-N 0.000 description 1
JEQKWIQAHBZXGN-UHFFFAOYSA-N 4-[[3-(1h-imidazol-2-ylmethyl)indol-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 JEQKWIQAHBZXGN-UHFFFAOYSA-N 0.000 description 1
UKYMVVJKIVMQQV-UHFFFAOYSA-N 4-chloro-n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1C2=CC=CC=C2C(CC=2NC=CN=2)=C1 UKYMVVJKIVMQQV-UHFFFAOYSA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
MQLJZFAKVWTELE-UHFFFAOYSA-N 4-indol-1-ylbutanoic acid Chemical compound C1=CC=C2N(CCCC(=O)O)C=CC2=C1 MQLJZFAKVWTELE-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
YUYWOJYXRRBNGX-UHFFFAOYSA-N 5-chloro-3-(1h-imidazol-2-ylmethyl)-1h-indole Chemical compound C12=CC(Cl)=CC=C2NC=C1CC1=NC=CN1 YUYWOJYXRRBNGX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
SPTHOEKISABNFX-UHFFFAOYSA-N OC(=S)S=N Chemical compound OC(=S)S=N SPTHOEKISABNFX-UHFFFAOYSA-N 0.000 description 1
101001041669 Oryctolagus cuniculus Corticostatin 1 Proteins 0.000 description 1
SGUKUZOVHSFKPH-UHFFFAOYSA-N PGG2 Natural products C1C2OOC1C(C=CC(OO)CCCCC)C2CC=CCCCC(O)=O SGUKUZOVHSFKPH-UHFFFAOYSA-N 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
206010049418 Sudden Cardiac Death Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
150000001348 alkyl chlorides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940054051 antipsychotic indole derivative Drugs 0.000 description 1
229940127217 antithrombotic drug Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
230000007214 atherothrombosis Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
230000003727 cerebral blood flow Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940005991 chloric acid Drugs 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
ACBHSRJWMKAASD-UHFFFAOYSA-N ethyl 5-(bromomethyl)thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(CBr)S1 ACBHSRJWMKAASD-UHFFFAOYSA-N 0.000 description 1
238000003810 ethyl acetate extraction Methods 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
230000004047 hyperresponsiveness Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
PWXMEBZOKUPCST-UHFFFAOYSA-N methyl 5-(chloromethyl)furan-2-carboxylate Chemical compound COC(=O)C1=CC=C(CCl)O1 PWXMEBZOKUPCST-UHFFFAOYSA-N 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
CHTGNBCTAFHZRQ-UHFFFAOYSA-N n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 CHTGNBCTAFHZRQ-UHFFFAOYSA-N 0.000 description 1
JVJIIDOXMXONMY-UHFFFAOYSA-N n-[2-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]ethyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NCCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 JVJIIDOXMXONMY-UHFFFAOYSA-N 0.000 description 1
NZCQVXBPLVYDLD-UHFFFAOYSA-N n-[3-[3-(1h-imidazol-2-ylmethyl)indol-1-yl]propyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NCCCN(C1=CC=CC=C11)C=C1CC1=NC=CN1 NZCQVXBPLVYDLD-UHFFFAOYSA-N 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
WMLPIEUKUSTHLK-UHFFFAOYSA-N o-methyl [n-(benzenesulfonyl)-s-methylsulfinimidoyl]methanethioate Chemical compound COC(=S)S(C)=NS(=O)(=O)C1=CC=CC=C1 WMLPIEUKUSTHLK-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
238000005956 quaternization reaction Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
230000008684 selective degradation Effects 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
208000014221 sudden cardiac arrest Diseases 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000006103 sulfonylation Effects 0.000 description 1
238000005694 sulfonylation reaction Methods 0.000 description 1
208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000029305 taxis Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
238000004804 winding Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LU82224A 1979-03-07 1980-03-05 Nouveaux 3-(1-imidazolylalkyl)indoles, leur procede de production et composition pharmaceutique les contenant LU82224A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB7908123		1979-03-07
GB7908123		1979-03-07

Publications (1)

Publication Number	Publication Date
LU82224A1 true LU82224A1 (fr)	1980-06-06

Family

ID=10503707

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU82224A LU82224A1 (fr)	1979-03-07	1980-03-05	Nouveaux 3-(1-imidazolylalkyl)indoles, leur procede de production et composition pharmaceutique les contenant

Country Status (36)

Country	Link
US (1)	US4273782A (de)
JP (1)	JPS55133380A (de)
KR (1)	KR850000760B1 (de)
AR (1)	AR227015A1 (de)
AT (1)	AT375366B (de)
AU (1)	AU516957B2 (de)
BE (1)	BE882113A (de)
CA (1)	CA1120479A (de)
CH (1)	CH649546A5 (de)
CS (1)	CS253702B2 (de)
DD (1)	DD149525A5 (de)
DE (1)	DE3008632A1 (de)
DK (1)	DK151884C (de)
ES (2)	ES8104278A1 (de)
FI (1)	FI66860C (de)
FR (1)	FR2450832A1 (de)
GR (1)	GR67237B (de)
HK (1)	HK89884A (de)
HU (1)	HU184727B (de)
IE (1)	IE49542B1 (de)
IL (1)	IL59524A (de)
IT (1)	IT1218420B (de)
KE (1)	KE3467A (de)
LU (1)	LU82224A1 (de)
MY (1)	MY8500285A (de)
NL (1)	NL182959C (de)
NO (1)	NO152217C (de)
NZ (1)	NZ193052A (de)
PH (1)	PH15198A (de)
PL (1)	PL128296B1 (de)
PT (1)	PT70914A (de)
SE (1)	SE440778B (de)
SG (1)	SG67284G (de)
SU (1)	SU1277894A3 (de)
YU (1)	YU41911B (de)
ZA (1)	ZA801328B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4414159A (en) *	1980-09-26	1983-11-08	E. I. Du Pont De Nemours & Co.	Vinyl ether monomers and polymers therefrom
US4444775A (en) *	1981-06-22	1984-04-24	Ciba-Geigy Corporation	Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) *	1981-07-07	1984-02-25	콘스탄틴 루이스 클레멘트	인돌 유도체의 제조방법
ZA825413B (en) *	1981-08-26	1983-06-29	Pfizer	Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4460777A (en) *	1981-11-19	1984-07-17	Ciba-Geigy Corporation	N-Substituted-2-pyridylindoles
US4478842A (en) *	1981-11-19	1984-10-23	Ciba-Geigy Corporation	N-Substituted-2-pyridylindoles
US4539410A (en) *	1982-09-30	1985-09-03	Ciba-Geigy Corporation	N-Substituted-2-(1-imidazolyl)indoles
US4436746A (en)	1982-09-30	1984-03-13	Ciba-Geigy Corporation	Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
AT376436B (de) *	1982-11-05	1984-11-26	Laevosan Gmbh & Co Kg	Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) *	1983-05-17	1985-04-16	Ciba-Geigy Corporation	3-Substituted-2-(heteroaryl) indoles
DE3786030T2 (de)	1986-03-27	1993-12-02	Merck Frosst Canada Inc	Tetrahydrocarbazole Ester.
JPH0832679B2 (ja) *	1986-09-05	1996-03-29	理化学研究所	Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) *	1986-11-28	1988-03-07	Glaxo Group Ltd	Process for the preparation of tricyclic ketones
KR920700210A (ko) *	1989-03-31	1992-02-19	기따미 가즈히꼬	신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
PT97888B (pt) *	1990-06-07	1998-12-31	Zeneca Ltd	Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
DE4023215A1 (de) *	1990-07-21	1992-01-23	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
KR930702334A (ko) *	1990-09-13	1993-09-08	데이비드 로버트	5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
US5162337A (en) *	1990-10-05	1992-11-10	Merck & Co., Inc.	Animal growth promotion
US5120749A (en) *	1991-02-20	1992-06-09	Abbott Laboratories	Platelet activating antagonists
MX9207393A (es) *	1991-12-18	1994-06-30	Schering Corp	Imidazoil o alquilo de imidazoil susbtituido con una cadena heterociclica de cuatro o cinco miembros que contienen nitrogeno.
US5538973A (en) *	1992-03-27	1996-07-23	Kyoto Pharmaceutical Industries, Ltd.	Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
CA2109931A1 (en) *	1992-03-27	1993-10-14	Hiroshi Matsui	Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) *	1992-09-18	1994-04-28	三洋電機株式会社	床暖房用パネル
CA2383983C (en) *	1998-03-31	2009-09-29	The Institutes For Pharmaceutical Discovery, Llc	Substituted indolealkanoic acids
NZ537979A (en) *	2002-09-12	2007-08-31	Hoffmann La Roche	N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
ATE405560T1 (de) *	2002-11-25	2008-09-15	Hoffmann La Roche	Indolderivaten
BR0316583A (pt) *	2002-12-10	2005-10-04	Wyeth Corp	Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
JP4682192B2 (ja) *	2004-05-03	2011-05-11	エフ．ホフマン−ラロシュアーゲー	肝ｘ受容体モジュレータとしてのインドリル誘導体
ATE499344T1 (de) *	2004-10-12	2011-03-15	Decode Genetics Ehf	Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
BRPI0615307A2 (pt) *	2005-08-25	2009-08-04	Schering Corp	agonistas de adrenorreceptor alfa2c
US7977359B2 (en) *	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) *	2005-11-04	2013-03-19	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) *	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
US7579483B2 (en) *	2006-05-16	2009-08-25	Decode Genetics, Ehf.	Process for preparing 7-(acryloyl)indoles
US7999119B2 (en)	2006-07-22	2011-08-16	Oxagen Limited	Compounds having CRTH2 antagonist activity
TW200920369A (en) *	2007-10-26	2009-05-16	Amira Pharmaceuticals Inc	5-lipoxygenase activating protein (flap) inhibitor
JP2011517313A (ja)	2007-12-11	2011-06-02	ビアメトファーマシューティカルズ，インク．	金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
US7750027B2 (en) *	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
AU2009204700B2 (en)	2008-01-18	2013-07-04	Atopix Therapeutics Limited	Compounds having CRTH2 antagonist activity
JP2011509991A (ja) *	2008-01-22	2011-03-31	オキサジェンリミテッド	Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2265581A1 (de) *	2008-01-22	2010-12-29	Oxagen Limited	Verbindungen mit crth2-antagonistischer wirkung
JP5791500B2 (ja) *	2008-05-23	2015-10-07	パンミラファーマシューティカルズ，エルエルシー．	５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en)	2008-10-01	2013-10-01	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
CA2877474A1 (en) *	2011-06-20	2012-12-27	Myrexis, Inc.	Compounds and therapeutic uses thereof
GB201322273D0 (en)	2013-12-17	2014-01-29	Atopix Therapeutics Ltd	Process
GB201407807D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407820D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
US11530186B2 (en) *	2018-03-29	2022-12-20	H. Lee Moffitt Cancer Center and Research Center Institute, Inc.	Inhibitors for the β-catenin / T-cell factor protein-protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL125443C (de) *	1963-06-06
US3370063A (en) *	1964-10-05	1968-02-20	Mcneilab Inc	Substituted dimethoxy indoles and method of making the same
US3621027A (en) *	1968-03-18	1971-11-16	Endo Lab	1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) *	1973-08-23	1976-01-06	Warner-Lambert Company	3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) *	1975-11-13	1977-11-22	Mcneil Laboratories, Incorporated	Substituted indoles
DK376078A (da) *	1977-08-26	1979-02-27	Wellcome Found	Fremgangsmaade til fremstilling af amidazoler
US4140858A (en) *	1977-12-19	1979-02-20	Warner-Lambert Company	3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
EP0003901B1 (de) *	1978-02-24	1981-08-05	Pfizer Limited	3-(Imidazol-1-ylalkyl) indole als selektive Thromboxansynthetase Hemmungsmittel, pharmazeutische Zusammensetzungen die diese enthalten und Verfahren zu ihrer Herstellung

1980
- 1980-01-31 DK DK042580A patent/DK151884C/da active
- 1980-03-04 CS CS801492A patent/CS253702B2/cs unknown
- 1980-03-04 HU HU80498A patent/HU184727B/hu not_active IP Right Cessation
- 1980-03-05 SU SU802891745A patent/SU1277894A3/ru active
- 1980-03-05 GR GR61368A patent/GR67237B/el unknown
- 1980-03-05 SE SE8001736A patent/SE440778B/sv not_active IP Right Cessation
- 1980-03-05 NZ NZ193052A patent/NZ193052A/en unknown
- 1980-03-05 YU YU614/80A patent/YU41911B/xx unknown
- 1980-03-05 ES ES489220A patent/ES8104278A1/es not_active Expired
- 1980-03-05 LU LU82224A patent/LU82224A1/fr unknown
- 1980-03-05 PL PL1980222470A patent/PL128296B1/pl unknown
- 1980-03-05 FI FI800672A patent/FI66860C/fi not_active IP Right Cessation
- 1980-03-05 IL IL59524A patent/IL59524A/xx unknown
- 1980-03-05 US US06/127,298 patent/US4273782A/en not_active Expired - Lifetime
- 1980-03-05 PH PH23726A patent/PH15198A/en unknown
- 1980-03-06 BE BE0/199699A patent/BE882113A/fr not_active IP Right Cessation
- 1980-03-06 KR KR1019800000931A patent/KR850000760B1/ko not_active Expired
- 1980-03-06 IT IT20399/80A patent/IT1218420B/it active
- 1980-03-06 NO NO800650A patent/NO152217C/no unknown
- 1980-03-06 AR AR280198A patent/AR227015A1/es active
- 1980-03-06 AT AT0125780A patent/AT375366B/de not_active IP Right Cessation
- 1980-03-06 PT PT70914A patent/PT70914A/pt not_active IP Right Cessation
- 1980-03-06 JP JP2856380A patent/JPS55133380A/ja active Granted
- 1980-03-06 ZA ZA00801328A patent/ZA801328B/xx unknown
- 1980-03-06 AU AU56231/80A patent/AU516957B2/en not_active Ceased
- 1980-03-06 DE DE19803008632 patent/DE3008632A1/de active Granted
- 1980-03-06 CH CH1781/80A patent/CH649546A5/de not_active IP Right Cessation
- 1980-03-06 FR FR8005054A patent/FR2450832A1/fr active Granted
- 1980-03-06 DD DD80219495A patent/DD149525A5/de not_active IP Right Cessation
- 1980-03-06 IE IE453/80A patent/IE49542B1/en not_active IP Right Cessation
- 1980-03-06 CA CA000347143A patent/CA1120479A/en not_active Expired
- 1980-03-06 NL NLAANVRAGE8001351,A patent/NL182959C/xx not_active IP Right Cessation
- 1980-11-14 ES ES496889A patent/ES496889A0/es active Granted
1984
- 1984-09-21 SG SG67284A patent/SG67284G/en unknown
- 1984-10-05 KE KE3467A patent/KE3467A/xx unknown
- 1984-11-15 HK HK898/84A patent/HK89884A/xx unknown
1985
- 1985-12-30 MY MY285/85A patent/MY8500285A/xx unknown

Also Published As

Publication number	Publication date
YU41911B (en)	1988-02-29
SU1277894A3 (ru)	1986-12-15
IL59524A0 (en)	1980-06-30
FI800672A7 (fi)	1980-09-08
DE3008632A1 (de)	1980-10-16
NL182959C (nl)	1988-06-16
CA1120479A (en)	1982-03-23
CH649546A5 (de)	1985-05-31
KE3467A (en)	1984-11-09
IE800453L (en)	1980-09-07
ES8205789A1 (es)	1982-08-01
GR67237B (de)	1981-06-25
JPS6141513B2 (de)	1986-09-16
PT70914A (en)	1980-04-01
IT1218420B (it)	1990-04-19
ZA801328B (en)	1981-03-25
CS253702B2 (en)	1987-12-17
AT375366B (de)	1984-07-25
DK151884B (da)	1988-01-11
FR2450832B1 (de)	1983-04-22
ES496889A0 (es)	1982-08-01
AU516957B2 (en)	1981-07-02
NO152217C (no)	1985-08-21
HK89884A (en)	1984-11-23
FI66860B (fi)	1984-08-31
BE882113A (fr)	1980-09-08
KR850000760B1 (ko)	1985-05-25
PL128296B1 (en)	1984-01-31
DE3008632C2 (de)	1988-02-25
HU184727B (en)	1984-10-29
KR830001928A (ko)	1983-05-19
ES489220A0 (es)	1981-04-01
NO152217B (no)	1985-05-13
AR227015A1 (es)	1982-09-15
PH15198A (en)	1982-09-17
SE440778B (sv)	1985-08-19
IT8020399A0 (it)	1980-03-06
NL8001351A (nl)	1980-09-09
FI66860C (fi)	1984-12-10
PL222470A1 (de)	1980-12-01
DD149525A5 (de)	1981-07-15
SG67284G (en)	1985-03-15
ES8104278A1 (es)	1981-04-01
YU61480A (en)	1983-12-31
US4273782A (en)	1981-06-16
ATA125780A (de)	1983-12-15
MY8500285A (en)	1985-12-31
IE49542B1 (en)	1985-10-30
AU5623180A (en)	1980-09-11
IL59524A (en)	1982-11-30
NO800650L (no)	1980-09-08
JPS55133380A (en)	1980-10-17
SE8001736L (sv)	1980-09-08
FR2450832A1 (fr)	1980-10-03
NZ193052A (en)	1984-07-06
DK151884C (da)	1988-06-13
DK42580A (da)	1980-09-08

Publication	Publication Date	Title
LU82224A1 (fr)	1980-06-06	Nouveaux 3-(1-imidazolylalkyl)indoles, leur procede de production et composition pharmaceutique les contenant
LU82087A1 (fr)	1980-04-23	N-benzylimidazoles inhibiteurs selectifs de thromboxannesynthetase,leur procede de production et compositions pharmaceutiques les contenant
EP0506532B1 (de)	1994-09-07	Indolderivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
LU81985A1 (fr)	1980-04-22	Nouveaux derives d'imidazole,leur procede de production et composition pharmaceutique les contenant
MC1241A1 (fr)	1979-10-26	Derives de l'imidazole et leur preparation et preparation de medicaments contenant ces substances
FR2658511A1 (fr)	1991-08-23	Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
JPH08509003A (ja)	1996-09-24	インドール誘導体トロンボキサンａ２アンタゴニスト
CH657359A5 (fr)	1986-08-29	Derives d'indole, procedes pour leur preparation et composition pharmaceutique les contenant.
CH651550A5 (fr)	1985-09-30	Derives de l'indole, leur preparation et compositions pharmaceutiques les contenant.
FR2741621A1 (fr)	1997-05-30	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
JP2007506772A (ja)	2007-03-22	Ｐａｉ−１としてのヘテロサイクリックまたはアリールオキシ、−チオまたは−アミノ置換インドール−２−カルボン酸またはエステル
WO2005094805A1 (ja)	2005-10-13	イミン誘導体及びアミド誘導体
CH642618A5 (fr)	1984-04-30	Phenethanolamines et compositions pharmaceutiques en contenant.
EP0040591A1 (de)	1981-11-25	Pyridoxin-Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP0069513B1 (de)	1987-03-04	Indolinhibitoren der Thromboxan-Synthetase, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0549407B1 (de)	1996-09-25	Neue Pyrrolidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
LU81598A1 (fr)	1981-03-24	Nouveaux derives d'imidazole,leur procede de production et composition pharmaceutique les contenant
GB2045244A (en)	1980-10-29	3-1-(Imidazolylalkyl) indoles
LU87129A1 (fr)	1988-09-20	Nouvel acide piperazinecarboxylique,sa preparation et son utilisation comme medicament
FR2641534A1 (fr)	1990-07-13	Nouveaux derives de glycine utiles comme medicaments antagonistes du thromboxane a2 et procede pour leur preparation
FR2543952A1 (fr)	1984-10-12	Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
FR2765580A1 (fr)	1999-01-08	Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
US4888352A (en)	1989-12-19	3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
EP0026168B1 (de)	1983-03-16	Decahydrochinolinolderivate, Verfahren zu ihrer Herstellung sowie ihre therapeutischen Verwendungen
MC1537A1 (fr)	1984-05-25	Derives d'imidazole et procede pour les preparer